266 related articles for article (PubMed ID: 22924958)
1. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
[TBL] [Abstract][Full Text] [Related]
2. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
Saijo K; Imai H; Chikamatsu S; Narita K; Katoh T; Ishioka C
Cancer Sci; 2017 Jul; 108(7):1469-1475. PubMed ID: 28406576
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
5. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
6. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
[TBL] [Abstract][Full Text] [Related]
7. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Son DS; Wilson AJ; Parl AK; Khabele D
Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Yu XD; Wang SY; Chen GA; Hou CM; Zhao M; Hong JA; Nguyen DM; Schrump DS
Cancer J; 2007; 13(2):105-13. PubMed ID: 17476138
[TBL] [Abstract][Full Text] [Related]
9. [Synthetic Study on Bicyclic Depsipeptides Containing an Intramolecular Disulfide Bond].
Narita K
Yakugaku Zasshi; 2022; 142(9):917-926. PubMed ID: 36047217
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
11. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
Imai H; Saijo K; Chikamatsu S; Kawamura Y; Ishioka C
Cancer Sci; 2021 Feb; 112(2):792-802. PubMed ID: 33274548
[TBL] [Abstract][Full Text] [Related]
12. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.
Mizutani H; Hiraku Y; Tada-Oikawa S; Murata M; Ikemura K; Iwamoto T; Kagawa Y; Okuda M; Kawanishi S
Cancer Sci; 2010 Oct; 101(10):2214-9. PubMed ID: 20624163
[TBL] [Abstract][Full Text] [Related]
13. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
15. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
Kodani M; Igishi T; Matsumoto S; Chikumi H; Shigeoka Y; Nakanishi H; Morita M; Yasuda K; Hitsuda Y; Shimizu E
Oncol Rep; 2005 Mar; 13(3):477-83. PubMed ID: 15706421
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
[TBL] [Abstract][Full Text] [Related]
17. FK228 sensitizes radioresistant small cell lung cancer cells to radiation.
Li H; Ma L; Bian X; Lv Y; Lin W
Clin Epigenetics; 2021 Feb; 13(1):41. PubMed ID: 33632300
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
An X; Wei Z; Ran B; Tian H; Gu H; Liu Y; Cui H; Zhu S
Anticancer Agents Med Chem; 2020; 20(17):2114-2124. PubMed ID: 32593284
[TBL] [Abstract][Full Text] [Related]
19. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
Wu D; Yan Y; Wei T; Ye Z; Xiao Y; Pan Y; Orme JJ; Wang D; Wang L; Ren S; Huang H
Cell Rep; 2021 Feb; 34(7):108744. PubMed ID: 33596421
[TBL] [Abstract][Full Text] [Related]
20. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]